Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Hughes

Showing results (291-300 of 305) with videos related to

Pageof 31
Sort By:
Molecular Pharmacology|November 3, 2007
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumorsStuart L Emanuel, Terry V Hughes, Mary Adams, et al.
American Journal of Veterinary Research|December 16, 2024
Immunization but not natural infection of horses results in antibody activity against the S protein of Streptococcus equi subsp equiNoah D Cohen, Emma V Hughes, Charlie Bayne, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.
Medicine|October 8, 2003
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patientsRicard Cervera, Munther A Khamashta, Josep Font, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase InhibitorsCurt D Haffner, Adam K Charnley, Christopher J Aquino, et al.
Journal of Clinical Immunology|November 7, 2003
Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndromeY Shoenfeld, I Krause, F Kvapil, et al.
Arthritis and Rheumatism|April 16, 2002
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsRicard Cervera, Jean-Charles Piette, Josep Font, et al.
The Journal of Rheumatology|July 2, 2004
Features associated with epilepsy in the antiphospholipid syndromeYehuda Shoenfeld, Shaul Lev, Ilan Blatt, et al.
Physical Review Letters|July 30, 2002
Measurement of analyzing power for proton-carbon elastic scattering in the coulomb-nuclear interference region with a 22-GeV/c polarized proton beamJ Tojo, I Alekseev, M Bai, et al.
Annals of the Rheumatic Diseases|September 20, 2008
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patientsR Cervera, M A Khamashta, Y Shoenfeld, et al.
Pageof 31

Showing results (291-300 of 305) with videos related to

Sort By:
Pageof 31
Molecular Pharmacology|November 3, 2007
Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumorsStuart L Emanuel, Terry V Hughes, Mary Adams, et al.
American Journal of Veterinary Research|December 16, 2024
Immunization but not natural infection of horses results in antibody activity against the S protein of Streptococcus equi subsp equiNoah D Cohen, Emma V Hughes, Charlie Bayne, et al.
Bioorganic & Medicinal Chemistry Letters|May 30, 2008
Discovery of novel 4-amino-6-arylaminopyrimidine-5-carbaldehyde oximes as dual inhibitors of EGFR and ErbB-2 protein tyrosine kinasesGuozhang Xu, Lily Lee Searle, Terry V Hughes, et al.
Medicine|October 8, 2003
Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patientsRicard Cervera, Munther A Khamashta, Josep Font, et al.
ACS Medicinal Chemistry Letters|November 22, 2019
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase InhibitorsCurt D Haffner, Adam K Charnley, Christopher J Aquino, et al.
Journal of Clinical Immunology|November 7, 2003
Prevalence and clinical correlations of antibodies against six beta2-glycoprotein-I-related peptides in the antiphospholipid syndromeY Shoenfeld, I Krause, F Kvapil, et al.
Arthritis and Rheumatism|April 16, 2002
Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patientsRicard Cervera, Jean-Charles Piette, Josep Font, et al.
The Journal of Rheumatology|July 2, 2004
Features associated with epilepsy in the antiphospholipid syndromeYehuda Shoenfeld, Shaul Lev, Ilan Blatt, et al.
Physical Review Letters|July 30, 2002
Measurement of analyzing power for proton-carbon elastic scattering in the coulomb-nuclear interference region with a 22-GeV/c polarized proton beamJ Tojo, I Alekseev, M Bai, et al.
Annals of the Rheumatic Diseases|September 20, 2008
Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patientsR Cervera, M A Khamashta, Y Shoenfeld, et al.
Pageof 31